Use of Low-Value Pediatric Services Among the Commercially Insured

Kao-Ping Chua1,2, Aaron L Schwartz3, Anna Volerman4,5

  • 1Sections of Academic Pediatrics, and kchua@peds.bsd.uchicago.edu.

Pediatrics
|December 13, 2016
PubMed

Insights

At least 1 in 10 children received low-value pediatric services in 2014, costing millions. Developing claims-based measures is crucial for reducing potentially harmful care for children.

Area of Science:

  • Pediatric healthcare utilization and quality measurement.
  • Health services research.
  • Evidence-based medicine implementation.

Background:

  • Developing claims-based measures for "low-value" pediatric services is essential for reducing potentially harmful care.
  • Few such validated measures currently exist, hindering intervention efforts.

Purpose of the Study:

  • To develop and apply novel claims-based measures for identifying low-value pediatric services.
  • To estimate the prevalence and cost of low-value pediatric service utilization in commercially insured US children.

Main Methods:

  • Developed claims-based measures for 20 identified low-value pediatric services.
  • Analyzed claims data from 4.4 million commercially insured US children (2014 Truven MarketScan database).
  • Calculated the proportion of children receiving at least one low-value service and associated costs, using both narrow and broad measure specifications.

Main Results:

  • Using narrow measures, 9.6% of children received at least one low-value service, totaling $27.0 million in spending ($9.2 million out-of-pocket).
  • Using broad measures, 14.0% of children received at least one low-value service.
  • Results demonstrate significant variation based on measure specification.

Conclusions:

  • A novel set of claims-based measures indicates that at least 1 in 10 children received low-value pediatric services in 2014.
  • Estimates of low-value pediatric service use are sensitive to the specific measures employed.
  • These findings highlight the need for robust measures to guide interventions aimed at improving pediatric care quality.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
345
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
411
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
645
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
306
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
605
Methods Of Healthcare Delivery System01:26

Methods Of Healthcare Delivery System

At the different levels of the healthcare system, we see varying methods of healthcare used. These methods include managed care systems, case management, and primary healthcare.
Managed Care System:
The managed care system is designed to control the cost while maintaining the quality of care. The patient's care from admission to discharge is planned by the primary care provider or the case manager, also known as the gatekeeper. In a managed care system, the number of care providers is...
4.2K